Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James B Bussel

Showing results (171-180 of 262) with videos related to

Pageof 27
Sort By:
Haematologica|July 13, 2019
Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopeniaHaiyu Zhang, Bing M Zhang, Xiangqian Guo, et al.
American Journal of Hematology|February 21, 2019
Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial programJames B Bussel, Donald M Arnold, Michael A Boxer, et al.
American Journal of Obstetrics and Gynecology|May 25, 2010
Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetusJames B Bussel, Richard L Berkowitz, Crystal Hung, et al.
Platelets|January 3, 2018
Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatmentWaleed Ghanima, Leonardo Boiocchi, Christina S Lee, et al.
Blood|May 8, 2014
A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopeniaJames B Bussel, David J Kuter, Louis M Aledort, et al.
British Journal of Haematology|September 10, 2011
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agentsWaleed Ghanima, Peter Junker, Hans Carl Hasselbalch, et al.
Transfusion|October 11, 2011
RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME)Jenny M Despotovic, Michele P Lambert, Jay H Herman, et al.
Haematologica|March 20, 2016
Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulationNicole Kucine, Aaron D Viny, Raajit Rampal, et al.
American Journal of Hematology|November 22, 2025
Daratumumab in Pediatric Chronic Refractory Primary Immune Thrombocytopenia (ITP): Rapid Platelet Recovery, Sustained Response, and Immune Reconstitution DynamicsYu Hu, Hui Chen, Zhifa Wang, et al.
Hematology (Amsterdam, Netherlands)|July 16, 2011
Single nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian adultsAmeet Sarpatwari, James B Bussel, Momin Ahmed, et al.
Pageof 27

Showing results (171-180 of 262) with videos related to

Sort By:
Pageof 27
Haematologica|July 13, 2019
Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopeniaHaiyu Zhang, Bing M Zhang, Xiangqian Guo, et al.
American Journal of Hematology|February 21, 2019
Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial programJames B Bussel, Donald M Arnold, Michael A Boxer, et al.
American Journal of Obstetrics and Gynecology|May 25, 2010
Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetusJames B Bussel, Richard L Berkowitz, Crystal Hung, et al.
Platelets|January 3, 2018
Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatmentWaleed Ghanima, Leonardo Boiocchi, Christina S Lee, et al.
Blood|May 8, 2014
A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopeniaJames B Bussel, David J Kuter, Louis M Aledort, et al.
British Journal of Haematology|September 10, 2011
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agentsWaleed Ghanima, Peter Junker, Hans Carl Hasselbalch, et al.
Transfusion|October 11, 2011
RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME)Jenny M Despotovic, Michele P Lambert, Jay H Herman, et al.
Haematologica|March 20, 2016
Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulationNicole Kucine, Aaron D Viny, Raajit Rampal, et al.
American Journal of Hematology|November 22, 2025
Daratumumab in Pediatric Chronic Refractory Primary Immune Thrombocytopenia (ITP): Rapid Platelet Recovery, Sustained Response, and Immune Reconstitution DynamicsYu Hu, Hui Chen, Zhifa Wang, et al.
Hematology (Amsterdam, Netherlands)|July 16, 2011
Single nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian adultsAmeet Sarpatwari, James B Bussel, Momin Ahmed, et al.
Pageof 27